$NTRA

Fesko John sold $440K of NTRA

Fesko John (PRESIDENT, CHIEF BUS. OFFICER) sold 1,713 shares of Natera, Inc. (NTRA) at an average of $257.00 ($254.07–$260.49, $0.44M total) across 2 trades over 2026-07-27 to 2026-07-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Fesko John
Published Jul 30, 2026, 1:35 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 30, 2026, 2:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NTRA
Neutral
high confidence
Mentioned
$NTRA
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosure provides transparency on executive share sales but does not introduce new company-specific catalysts like earnings, guidance, trials, deals, or regulatory actions.

02

Market read

For NTRA, this is primarily a sentiment datapoint rather than a fundamental driver.

03

What to watch

Traders may over-weight insider selling; the key incremental data here is only the disclosed sale size and timing, not any change in guidance or business performance.

Relevance 3/10Novelty 3/10Timing: after-hours SEC Form 4 filing dated 2026-07-29 for sales on 2026-07-27 to 2026-07-28

Background

The article is an SEC Form 4 insider transaction disclosure for Natera, Inc.

Company-level read

Ticker impact

$NTRANeutralHigh confidence
Context

Natera insider Form 4 shows President/COO Fesko John sold about 1,713 shares for roughly $440K under a 10b5-1 plan.

Expected impact

Likely minimal, with any effect confined to short-term sentiment rather than a fundamental repricing.

Evidence & confidence

The filing is a disclosed insider transaction, but it is explicitly pre-arranged under Rule 10b5-1 and does not include new operating, financial, or regulatory information.

Market effects

No clear read-across to the broader biotech/diagnostics sector from a single routine 10b5-1 sale.

None.

None.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations.

Key entities

  • Natera, Inc.

    Company whose insider transaction is disclosed on Form 4.

  • Fesko John

    President and Chief Business Officer who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either.

Billionaire investor Stanley Druckenmiller's largest Q2 holding was Natera (NTRA), a genetic testing company, not Amazon or Alphabet. Natera reported Q2 2026 revenue of $752.8M, up 39% YoY, and raised full-year guidance to $2.85B-$2.91B. The company's Signatera cancer detection test is a key growth driver, with FDA, PMDA, and EU approvals.

$NTRAMedAI 8/10

Natera (NTRA) Q2 2026 Earnings Call Transcript

Natera (NTRA) reported Q2 2026 revenue of $752.8 million, up 37.7% year over year, and net loss per diluted share of ($0.47), improved from ($0.74). Total tests processed rose 22.4% to 1,043,900. The company raised full-year revenue guidance to $2.85 billion to $2.91 billion and cited FDA and PMDA approvals for Signatera.

$NTRAHighAI 9/10

Natera Stock Jumps After Q2 Beat And Guidance Hike

Natera Inc. (NTRA) shares rose about 20.9% after Q2 results and guidance. Q2 revenue was $752.8M versus $661.2M consensus, with a Q2 loss of $0.47 per share versus $0.49 expected. Full-year 2026 revenue guidance was raised to $2.85B to $2.91B. The Signatera test was submitted to Japan’s PMDA for muscle-invasive bladder cancer.